Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associ ...